{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Temozolomide+and+Radiation+Alone&page=3", "query": { "intervention": "Temozolomide and Radiation Alone", "page": 3 }, "page_size": 10 }, "pagination": { "page": 3, "page_size": 10, "total_count": 74, "total_pages": 8, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Temozolomide+and+Radiation+Alone&page=4&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Temozolomide+and+Radiation+Alone&page=2&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-07T22:52:22.526Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00039494", "title": "Erlotinib and Temozolomide With Radiation Therapy in Treating Patients With Glioblastoma Multiforme or Other Brain Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Adult Giant Cell Glioblastoma", "Adult Glioblastoma", "Adult Gliosarcoma" ], "interventions": [ { "name": "erlotinib hydrochloride", "type": "DRUG" }, { "name": "3-dimensional conformal radiation therapy", "type": "RADIATION" }, { "name": "temozolomide", "type": "DRUG" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 171, "start_date": "2002-12", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-08-02", "last_synced_at": "2026-10-07T22:52:22.526Z", "location_count": 139, "location_summary": "Mobile, Alabama • Scottsdale, Arizona • Jacksonville, Florida + 82 more", "locations": [ { "city": "Mobile", "state": "Alabama" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Athens", "state": "Georgia" }, { "city": "Aurora", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT00039494" }, { "nct_id": "NCT02659800", "title": "Study of the Effect NT-I7 on CD4 Counts in Patients With High Grade Gliomas", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Lymphopenia", "Malignant Glioma" ], "interventions": [ { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "NT-I7", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "OTHER", "BIOLOGICAL" ], "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 12, "start_date": "2018-10-30", "completion_date": "2023-10-03", "has_results": false, "last_update_posted_date": "2023-10-06", "last_synced_at": "2026-10-07T22:52:22.526Z", "location_count": 10, "location_summary": "Birmingham, Alabama • Baltimore, Maryland • Boston, Massachusetts + 7 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Detroit", "state": "Michigan" }, { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT02659800" }, { "nct_id": "NCT01186406", "title": "Gliadel, XRT, Temodar, Avastin Followed by Avastin, Temodar for Newly Diagnosed Glioblastoma Multiforme (GBM)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Glioblastoma Multiforme", "Gliosarcoma" ], "interventions": [ { "name": "Gliadel", "type": "DRUG" }, { "name": "Radiation Therapy", "type": "RADIATION" }, { "name": "Avastin", "type": "DRUG" }, { "name": "Temodar", "type": "DRUG" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "Duke University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 41, "start_date": "2011-04", "completion_date": "2014-06-16", "has_results": true, "last_update_posted_date": "2019-02-15", "last_synced_at": "2026-10-07T22:52:22.526Z", "location_count": 1, "location_summary": "Durham, North Carolina", "locations": [ { "city": "Durham", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT01186406" }, { "nct_id": "NCT02287428", "title": "Personalized NeoAntigen Cancer Vaccine w RT Plus Pembrolizumab for Patients With Newly Diagnosed GBM", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Glioblastoma" ], "interventions": [ { "name": "Radiation Therapy", "type": "RADIATION" }, { "name": "Personalized NeoAntigen Peptides", "type": "BIOLOGICAL" }, { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Temozolomide", "type": "DRUG" }, { "name": "Poly-ICLC", "type": "BIOLOGICAL" } ], "intervention_types": [ "RADIATION", "BIOLOGICAL", "DRUG" ], "sponsor": "Dana-Farber Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 56, "start_date": "2014-11", "completion_date": "2028-02", "has_results": false, "last_update_posted_date": "2026-04-17", "last_synced_at": "2026-10-07T22:52:22.526Z", "location_count": 2, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT02287428" }, { "nct_id": "NCT02864368", "title": "Peptide Targets for Glioblastoma Against Novel Cytomegalovirus Antigens", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Glioblastoma", "Glioblastoma Multiforme" ], "interventions": [ { "name": "5-day TMZ", "type": "DRUG" }, { "name": "21-day TMZ", "type": "DRUG" }, { "name": "PEP-CMV: Component A", "type": "BIOLOGICAL" }, { "name": "Tetanus-Diphtheria booster", "type": "DRUG" }, { "name": "Tetanus Pre-Conditioning", "type": "DRUG" }, { "name": "PEP-CMV: Component B", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Eric Thompson, M.D.", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 27, "start_date": "2016-12-07", "completion_date": "2020-06-15", "has_results": true, "last_update_posted_date": "2022-06-09", "last_synced_at": "2026-10-07T22:52:22.526Z", "location_count": 1, "location_summary": "Durham, North Carolina", "locations": [ { "city": "Durham", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT02864368" }, { "nct_id": "NCT00685750", "title": "Expression Analysis of Specific Markers in Non-small Cell Lung Cancer or Melanoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Lung Cancer, Non-Small Cell" ], "interventions": [ { "name": "Collection of tumor and blood samples", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 88, "start_date": "2008-04-28", "completion_date": "2013-12-17", "has_results": true, "last_update_posted_date": "2019-06-20", "last_synced_at": "2026-10-07T22:52:22.526Z", "location_count": 4, "location_summary": "Los Angeles, California • Park Ridge, Illinois • St Louis, Missouri + 1 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Park Ridge", "state": "Illinois" }, { "city": "St Louis", "state": "Missouri" }, { "city": "Murray", "state": "Utah" } ], "official_url": "https://clinicaltrials.gov/study/NCT00685750" }, { "nct_id": "NCT01933815", "title": "Dose-Escalation Study of TPI 287 + Avastin Followed by Randomized Study of the Same Versus Avastin for Glioblastoma", "overall_status": "SUSPENDED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Glioblastoma Multiforme" ], "interventions": [ { "name": "TPI 287", "type": "DRUG" }, { "name": "Bevacizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Cortice Biosciences, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 92, "start_date": "2013-08", "completion_date": "2025-05", "has_results": false, "last_update_posted_date": "2023-02-22", "last_synced_at": "2026-10-07T22:52:22.526Z", "location_count": 9, "location_summary": "Birmingham, Alabama • St Louis, Missouri • Hackensack, New Jersey + 6 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "St Louis", "state": "Missouri" }, { "city": "Hackensack", "state": "New Jersey" }, { "city": "Commack", "state": "New York" }, { "city": "Lake Success", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT01933815" }, { "nct_id": "NCT00112502", "title": "Temozolomide Alone or in Combination With Thalidomide and/or Isotretinoin and/or Celecoxib in Treating Patients Who Have Undergone Radiation Therapy for Glioblastoma Multiforme", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Brain and Central Nervous System Tumors", "Glioblastoma Multiforme" ], "interventions": [ { "name": "Celecoxib", "type": "DRUG" }, { "name": "Isotretinoin", "type": "DRUG" }, { "name": "Temozolomide", "type": "DRUG" }, { "name": "Thalidomide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 178, "start_date": "2005-09", "completion_date": "2014-09", "has_results": true, "last_update_posted_date": "2021-10-18", "last_synced_at": "2026-10-07T22:52:22.526Z", "location_count": 12, "location_summary": "Fort Smith, Arkansas • Orlando, Florida • Atlanta, Georgia + 9 more", "locations": [ { "city": "Fort Smith", "state": "Arkansas" }, { "city": "Orlando", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Decatur", "state": "Illinois" }, { "city": "Wichita", "state": "Kansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00112502" }, { "nct_id": "NCT04478279", "title": "A Phase 1-2 Study of ST101 in Patients With Advanced Solid Tumors", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Glioblastoma", "Melanoma Stage IV", "Breast Cancer", "Prostate Cancer", "Glioblastoma Multiforme", "GBM", "Brain Cancer", "Metastatic Breast Cancer", "Metastatic Melanoma", "Metastatic Prostate Cancer", "Melanoma Recurrent", "Prostate Cancer Metastatic", "Recurrent Glioblastoma", "Newly Diagnosed Glioblastoma" ], "interventions": [ { "name": "ST101", "type": "DRUG" }, { "name": "Temozolomide", "type": "DRUG" }, { "name": "Radiation", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "Sapience Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 125, "start_date": "2020-07-01", "completion_date": "2026-12", "has_results": false, "last_update_posted_date": "2026-02-09", "last_synced_at": "2026-10-07T22:52:22.526Z", "location_count": 7, "location_summary": "San Francisco, California • Denver, Colorado • Warrenville, Illinois + 4 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Warrenville", "state": "Illinois" }, { "city": "Grand Rapids", "state": "Michigan" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT04478279" }, { "nct_id": "NCT00187486", "title": "Safety and Efficacy Study of Tarceva, Temodar, and Radiation Therapy in Patients With Newly Diagnosed Brain Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Glioblastoma Multiforme", "Gliosarcoma" ], "interventions": [ { "name": "Tarceva", "type": "DRUG" }, { "name": "Temodar", "type": "DRUG" }, { "name": "Radiation Therapy", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "University of California, San Francisco", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 66, "start_date": "2004-08", "completion_date": "2011-03", "has_results": true, "last_update_posted_date": "2017-09-05", "last_synced_at": "2026-10-07T22:52:22.526Z", "location_count": 1, "location_summary": "San Francisco, California", "locations": [ { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00187486" } ] }